Search Results


Your search for Richard Champlin, MD matches 5 pages

Showing 1 - 5

hematologic malignancies

Participating in ‘Tremendous Progress’ in Hematologic Oncology, From Chernobyl to Stem Cell Transplantation

Richard E. Champlin, MD, Chairman of the nation’s largest Stem Cell Transplantation and Cellular Therapy program at The University of Texas MD Anderson Cancer Center, was born in Milwaukee and spent his formative years in Chicago. After high school, Dr. Champlin followed an early ambition in...


Treatment of Relapse of Acute Leukemia Post-Transplant: Still Hope for Patients With Chemosensitive Disease 

Disease recurrence is a devastating event after allogeneic hematopoietic stem cell transplantation as treatment for acute myeloid leukemia (AML). Median time to relapse is approximately 4 months and the majority of relapses occur within 2 years after transplant. The prognosis is usually poor....

ASCO Members Reflect on ‘Lessons From Chernobyl’

As part of ASCO’s 50th anniversary, the Society has published a weekly series on special moments in its history. In this edition of The ASCO Post, we revisit a unique time when ASCO’s history intersected with major world events. To read the entire series, visit the “News and Views” page on...

MD Anderson Names Patrick Hwu, MD, Head of Cancer Medicine

Patrick Hwu, MD, Chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, has been named Division Head of Cancer Medicine. He will take over from Richard Champlin, MD, who has been acting Division Head on an ad interim basis. Dr. ...

Marked Increase in Fracture Risk in Patients Receiving Hematopoietic Stem Cell Transplantation

In a single-institution retrospective study reported in the Journal of Clinical Oncology, Pundole et al found that patients undergoing hematopoietic stem cell transplantation are at increased risk of bone fracture later in life, with risk being particularly elevated in women and men aged 45 to 64...